ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Anti-Perlecan Antibodies Are Novel Accelerators of Immune-Mediated Vascular Injury

M. Dieudé, S. Qi, D. Beillevaire, N. Patey, M. Hebert

Research Centre, Centre Hospitalier de l'Université
de Montréal (CRCHUM), Montréal, QC, Canada
Research Centre, Hopital Sainte-Justine, Montréal, QC, Canada

Meeting: 2013 American Transplant Congress

Abstract number: D1460

Acute vascular rejection (AVR) is characterized by immune-mediated vascular injury and heightened endothelial cell (EC) apoptosis. We previously reported that apoptotic ECs release a bioactive C-terminal fragment of perlecan referred to as LG3 and that anti-LG3 IgG titers are increased in renal transplant patients with acute vascular rejection. Here, we evaluate the potential role of anti-LG3 antibodies as accelerators of vascular injury in a murine model of vascular rejection. Methods We performed passive transfer of 50 ug of anti-LG3 or 50 ug of control IgG every other day during three weeks in an animal model of vascular rejection based on orthotopic aortic transplantation between fully MHC-mismatched mice or in isografted mice as controls. The importance of pre-transplant ischemia for intravascular deposition of anti-LG3 was tested by submitting the aorta to warm ischemia for 15 minutes before harvesting. Transplanted aortas were harvested at 3 weeks post-transplantation. Aortic sections were H/E stained or immunohistochemistry was performed for the detection of NK cells (GM1 Asialo), T cells (CD3) or C4d deposition. Results Passive transfer of anti-LG3 IgGs in mice transplanted with a non-ischemic allograft led to a modest increase in neointima formation (p=0.17). Passive transfer of anti-LG3 in recipients of an ischemic isograft led to a trend towards increased neointima formation but this did not reach statistical significance (p=0.6). In ischemic allografts however, passive anti-LG3 transfer induced striking NK and T cell infiltration (p=0.003 and 0.03 respectively), C4d deposition and enhanced obliterative vascular remodelling(p=0.04). Conclusion These results suggest that anti-LG3 antibodies significantly increase vascular inflammation and obliterative remodelling in allografts exposed to an initial ischemic insult followed by ongoing immune-mediated vascular injury. These data identify anti-LG3 antibodies as novel accelerators of immune-mediated vascular injury and obliterative remodelling.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Dieudé M, Qi S, Beillevaire D, Patey N, Hebert M. Anti-Perlecan Antibodies Are Novel Accelerators of Immune-Mediated Vascular Injury [abstract]. Am J Transplant. 2013; 13 (suppl 5). https://atcmeetingabstracts.com/abstract/anti-perlecan-antibodies-are-novel-accelerators-of-immune-mediated-vascular-injury/. Accessed May 17, 2025.

« Back to 2013 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences